A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 09 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2017.